Physician

Charles Lance Cowey, M.D.

According to 2025 Medicare claims, Charles Cowey, M.D. (NPI: 1033358288) practices medical oncology in the Dallas-Plano-Irving, TX market, with the plurality of this provider's patient population coming from Dallas, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1003083445; TIN: 752131429) and primary practice location at 75246-2012.

Cowey's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 646 traditional Medicare patients, billed 136,116 HCPCS/CPT codes, and received $3,457,349 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,189 prescription claims across 210 beneficiaries totaling $3,508,696 in drug costs, led by Cabometyx (Cabozantinib S-Malate). DME data shows 13 claims. Open Payments data shows 236 records totaling $1,179,710. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $722,945 to $3,508,696. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	239	51,699	$2,985,727
2016	437	108,457	$2,280,948
2017	500	115,007	$1,795,234
2018	502	105,020	$1,936,404
2019	532	114,481	$1,995,805
2020	532	108,263	$1,963,868
2021	631	94,525	$2,028,180
2022	589	107,253	$2,167,155
2023	584	130,564	$2,802,071
2024	646	136,116	$3,457,349

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	92	766	$722,945
2016	92	722	$1,142,868
2017	96	664	$749,801
2018	107	817	$1,471,775
2019	87	775	$1,397,394
2020	98	793	$1,809,706
2021	100	856	$2,084,963
2022	98	812	$2,134,958
2023	118	792	$1,649,883
2024	210	1,189	$3,508,696

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	13	$649

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	229	427	$96
80053	Blood test, comprehensive group of blood chemicals	286	983	$10
36415	Insertion of needle into vein for collection of blood sample	285	941	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	279	953	$8
83615	Lactate dehydrogenase (enzyme) level	210	705	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Cabometyx	Cabozantinib S-Malate	18	540	$460,104
Inlyta	Axitinib	23	690	$418,917
Lenvima	Lenvatinib Mesylate	16	480	$374,266
Mektovi	Binimetinib	23	690	$339,062
Xtandi	Enzalutamide	24	720	$334,093

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk	Y	N/R	13	$649

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$184	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	226	$1,179,525	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles Lance Cowey, M.D.?

Tedicare shows public-source Medicare data for Charles Lance Cowey, M.D. (NPI 1033358288), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Lance Cowey, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Charles Lance Cowey, M.D.?

Charles Lance Cowey, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1003083445) in the available physician profile data.

Does Charles Lance Cowey, M.D. have Open Payments data?

Charles Lance Cowey, M.D. has 236 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.